StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
LRMRLarimar Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$2.35▼ 0.21%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $244.1MShares out 100M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

5
  • 10.1After-hours26.10.02 05:27
    4Ownership#●●●

    Larimar Therapeutics, Inc.

    Larimar Therapeutics insider John B. Harlow Jr. filed a Form 4 on October 1, 2026, reporting a change in beneficial ownership of securities as of September 29, 2026. This filing serves as the official record of the insider's transaction.…more

    $2.35-0.21%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.1After-hours26.10.02 05:26
    3Ownership

    Larimar Therapeutics, Inc.

    Insider John B. Harlow Jr. of Larimar Therapeutics, Inc. filed a Form 3 on October 1, 2026, reporting his beneficial ownership of securities as of September 29, 2026. This filing serves as the initial statement of securities ownership for the reporting individual.…more

    $2.35-0.21%vs prev close
    View filingShare
  • 9.29After-hours26.09.30 05:06
    8-KKey event

    Larimar Therapeutics, Inc.

    Larimar Therapeutics appointed John B. Harlow, Jr. as President and Chief Operating Officer, effective September 29, 2026. As part of his compensation package, he will receive an annual base salary of $560,000, along with an inducement grant of 800,000 stock options and 50,000 restricted stock units.…more

    $2.35-0.21%vs prev close
    View filingShare

4 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.29After-hours26.09.30 05:06
    #●●●#●●●

    Larimar Therapeutics Appoints John Harlow as President and COO

    Larimar Therapeutics has appointed John Harlow, a biopharmaceutical veteran with over 25 years of experience, as its new President and COO. While the leadership addition aims to strengthen operations, it does not provide immediate financial or clinical catalysts for the stock.…more

    $2.35-0.21%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 8.4Pre-market26.08.04 20:00

    ●●●●●●●● ●●●●● ●●●●●●

    라리마 테라퓨틱스는 프리드라이히 운동실조증 치료제 '노믈라보퍼스프'의 임상 데이터가 긍정적인 결과를 보임에 따라 신속 승인을 위한 생물학적 제제 허가 신청(BLA) 절차를 시작했습니다. 2027년 3분기까지 운영 가능한 자금을 확보한 가운데, 올해 하반기 BLA 제출 완료 및 글로벌 임상 3상 투약을 앞두고 있습니다.…more

    $2.35-0.21%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →